The UBC-40 Urothelial Bladder Cancer cell line index: A genomic resource for functional studies

BMC Genomics

Volumn 16, Issue 1, 2015, Pages

  Earl, Julie ^a,b   Rico, Daniel ^a   Carrillo de Santa Pau, Enrique ^a   Rodríguez Santiago, Benjamín ^c,d,e   Méndez Pertuz, Marinela ^a   Auer, Herbert ^f   Gómez, Gonzalo ^a   Grossman, Herbert Barton ^g   Pisano, David G ^a   Schulz, Wolfgang A ^h   Pérez Jurado, Luis A ^d,e   Carrato, Alfredo ^b   Theodorescu, Dan ⁱ   Chanock, Stephen ^j   Valencia, Alfonso ^a   Real, Francisco X ^a,d  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Quantitative Genomic Medicine Laboratories   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^f INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Cell line; Genomics; Mutation; Oncogene; Tumor suppressor; Urothelial bladder cancer

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; FGFR3 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P53; RAS PROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CHROMOSOME LOSS; CONTROLLED STUDY; FGFR3 GENE; GENE; GENE DOSAGE; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC RESOURCE; HUMAN; HUMAN CELL; TP53 GENE; TUMOR SUPPRESSOR GENE; BLADDER TUMOR; CLUSTER ANALYSIS; COPY NUMBER VARIATION; FEMALE; GENETIC DATABASE; GENETICS; GENOMIC INSTABILITY; HUMAN GENOME; MALE; PATHOLOGY; TUMOR CELL LINE; X CHROMOSOME;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, X; CLUSTER ANALYSIS; DATABASES, GENETIC; DNA COPY NUMBER VARIATIONS; FEMALE; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; RAS PROTEINS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84935895322     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-015-1450-3     Document Type: Article

References (49)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int Cancer. 2010;127(12):2893-917.
2. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25(3):285-95.
3. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, Tardon A, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664-71.
4. Luis NM, Lopez-Knowles E, Real FX. Molecular biology of bladder cancer. Clin Transl Oncol. 2007;9(1):5-12.
5. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23(1):18-20.
6. Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, Carrato A, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006;66(15):7401-4.
7. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24(33):5218-25.
8. Real FX. p53: it has it all, but will it make it to the clinic as a marker in bladder cancer? J Clin Oncol. 2007;25(34):5341-4.
9. Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer J Int Cancer. 2006;119:1513-8.
10. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 2010;70(9):3463-72.
11. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 2005;11(19 Pt 1):7012-22.
12. Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377-86.
13. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Europ Urol. 2014;65(2):360-6.
14. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-7.
15. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813-23.
16. Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene. 2004;23(12):2250-63.
17. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013;22(4):795-803.
18. Carro A, Rico D, Rueda OM, Diaz-Uriarte R, Pisano DG. waviCGH: a web application for the analysis and visualization of genomic copy number alterations. Nucleic Acids Res. 2010;38(Web Server issue):W182-7.
19. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Marquez M, Vazquez M, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet. 2013;45(12):1464-9.
20. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011;43(9):875-8.
21. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature Genet. 2013;45(12):1459-63.
22. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22.
23. Balbas-Martinez C, Rodriguez-Pinilla M, Casanova A, Dominguez O, Pisano DG, Gomez G, et al. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS One. 2013;8(5):e62483.
24. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nature Genet. 2013;45(12):1428-30.
25. Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C, Chapeaublanc E, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014;6(244):244ra291.
26. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, et al. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther. 2009;8(4):713-24.
27. O'Toole CM, Povey S, Hepburn P, Franks LM. Identity of some human bladder cancer cell lines. Nature. 1983;301(5899):429-30.
28. Jager W, Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, et al. Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol. 2013;190(4):1404-9.
29. Warenius HM, Jones M, Gorman T, McLeish R, Seabra L, Barraclough R, et al. Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. Br J Cancer. 2000;83(8):1084-95.
30. Qing J, Du X, Chen Y, Chan P, Li H, Wu P, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest. 2009;119(5):1216-29.
31. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2009;85(2):217-21.
32. Seifert HH, Meyer A, Cronauer MV, Hatina J, Muller M, Rieder H, et al. A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J Urol. 2007;25(3):297-302.
33. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(Database issue):D945-50.
34. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-9.
35. Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, Zou C, et al. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol. 2006;175(3 Pt 1):1133-7.
36. Yeager TR, DeVries S, Jarrard DF, Kao C, Nakada SY, Moon TD, et al. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev. 1998;12(2):163-74.
37. Hatina J, Huckenbeck W, Rieder H, Seifert HH, Schulz WA. [Bladder carcinoma cell lines as models of the pathobiology of bladder cancer. Review of the literature and establishment of a new progression series]. Der Urologe Ausg A. 2008;47(6):724-34.
38. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5(11):e13821.
39. Pounds S, Cheng C, Mullighan C, Raimondi SC, Shurtleff S, Downing JR. Reference alignment of SNP microarray signals for copy number analysis of tumors. Bioinformatics. 2009;25(3):315-21.
40. Rodriguez-Santiago B, Malats N, Rothman N, Armengol L, Garcia-Closas M, Kogevinas M, et al. Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. Am J Hum Genet. 2010;87(1):129-38.
41. Team RDC. R: A language and environment for statistical computing. 2008.
42. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004;5(4):557-72.
43. van de Wiel MA, Kim KI, Vosse SJ, van Wieringen WN, Wilting SM, Ylstra B. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics. 2007;23(7):892-4.
44. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics. 2010;11(2):242-53.
45. Rieger KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, et al. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer. 1995;72(3):683-90.
46. Sarkar S, Julicher KP, Burger MS, Della Valle V, Larsen CJ, Yeager TR, et al. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res. 2000;60(14):3862-71.
47. Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res. 2011;17(9):2863-73.
48. Koch A, Hatina J, Rieder H, Seifert HH, Huckenbeck W, Jankowiak F, et al. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines. Cell Oncol. 2012;35(4):243-57.
49. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol. 2014;65(2):367-9.